New 6-Month drug cocktail aims to tame resistant TB
NCT ID NCT07675954
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a 6-month combination of five drugs (bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide) works as well as standard treatment for rifampicin-resistant tuberculosis in adults and adolescents aged 15 and older in South Africa. The study also checks if this new regimen causes fewer side effects. Participants are randomly assigned to either the experimental or standard treatment and followed for 12 months after therapy ends.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MDR-END Plus regimen (bedaquiline, delamanid, delpazolid, levofloxacin, pyrazinamide)
- What this could lead to
- If successful, this could provide a shorter, safer, and more tolerable treatment option for drug-resistant tuberculosis, potentially improving cure rates.
- What could go wrong
- This is a phase 3 trial, but results may not confirm non-inferiority or safety advantages. The regimen may still cause side effects or require treatment extensions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFAMPICIN-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Desmond Tutu TB Centre, Brooklyn Chest Hospital Trial Unit
Cape Town, Western Cape, 7405, South Africa
Contact Email: •••••@•••••
-
Perinatal HIV Research Unit, PHRU-Matlosana, Tshepong Hospital
Klerksdorp, North West, 2571, South Africa
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sputum DNA test aims to outsmart Drug-Resistant TB
- New hope for kids with Drug-Resistant TB: pretomanid dose study completed
- New hope against Drug-Resistant TB: phase II trial launches
- New 9-Month pill regimen could tackle Drug-Resistant TB
- Massive global study aims to slash TB deaths with smarter testing
- Could a 6-Month pill combo beat Drug-Resistant TB?